Ÿ·Î´Ï½ºÅ¸Æ¾½Ã·´ 6MI.U/60mL TARONYSTATIN SYRUP
Àü¹®ÀǾàǰ | ºñ±Þ¿©
¼öÀÔÀǾàǰ
¾Ë¸²:
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù.
Àü¹®/ÀϹÝ
Àü¹®
Ȳ»öÀÇ ºÒÅõ¸íÇÑ ÇöŹ ½Ã·´
Á¦Á¶È¸»ç
Taro pharmaceuticals
ÆÇ¸Åȸ»ç
¸í¹®Á¦¾à(ÁÖ)
Çã°¡Á¤º¸
ÃëÇÏ
(2023.01.01)
BIT ¾àÈ¿ºÐ·ù
Ç×Áø±ÕÁ¦ (Antifungal Agents)
º¹ÁöºÎºÐ·ù
616[ÁÖ·Î °õÆÎÀÌ, ¿øÃæ¿¡ ÀÛ¿ëÇÏ´Â °Í ]
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå
649806031[649806030] [ºñ±Þ¿©]
ATCÄÚµå
Nystatin / A07AA02
NDCÄÚµå
[Proprietary Name Search _ ƯÇãµî·Ï¸í,»óÇ¥¸íÀ¸·Î °Ë»ö]
[Active Ingredient Search _ ÁÖ¼ººÐÀ¸·Î °Ë»ö]
[NDC Number Search _ NDCÄÚµå·Î °Ë»ö]
¼ººÐ / ÇÔ·®
[½ÉÆò¿ø ÁÖ¼ººÐÄÚµå ±âÁØ ¼ººÐÇÔ·®Á¤º¸ Á¶È¸]
÷°¡Á¦
±Û¸®¼¼¸° ,
¸¶±×³×½·¾Ë·ç¹Ì´½½Ç¸®ÄÉÀÌÆ® ,
º¥Áî¾Ëµ¥È÷µå ,
»çÄ«¸°³ªÆ®·ý¼öȹ° ,
¼öÅ©·Î½º ,
½ÃÆ®¸£»ê³ªÆ®·ý¼öȹ° ,
¿¡µ¥Æ®»êÄ®½·³ªÆ®·ý¼öȹ° ,
¿¡Åº¿Ã ,
¿ÍÀϵåü¸®Ç÷¹À̹ö #16117 ,
ÀÜź°Ë ,
Á¤Á¦¼ö ,
ÆÄ¶ó¿Á½Ãº¥Á¶»ê¸ÞÆ¿ ,
ÆÄ¶ó¿Á½Ãº¥Á¶»êÇÁ·ÎÇÊ ,
ÆäÆÛ¹ÎÆ® 501.500T
À¯·áȸ¿ø °áÀç½Ã ¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸ ¸¦
ÀÌ¿ë ÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·Ï Àº Àü¹®È¸¿ø À¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
Çã°¡Á¤º¸
Ç׸ñ
³»¿ë
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇѱݾ×
649806031[649806030]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
[ºñ±Þ¿©]
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁý ´Ù¿î·Îµå]
[¿ì¸®Áý°Ç°ÁÖÄ¡ÀÇ ¹Ù·Î°¡±â]
ºü¸¥Á¶È¸
Á¦Ç°¼º»ó
Ȳ»öÀÇ ºÒÅõ¸íÇÑ ÇöŹ ½Ã·´
[Á¦ÇüÁ¤º¸ È®ÀÎ]
Æ÷À塤À¯Åë´ÜÀ§
60mL/1º´
ÁÖ¼ººÐÄÚµå
203530ASY
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
´ëÇ¥ÄÚµå
8806498060302
º¸°ü¹æ¹ý
Â÷±¤ÇÑ ±â¹Ð¿ë±â, 25¡ÉÀÌÇÏ ½Ç¿Âº¸°ü
¾à¸®ÀÛ¿ë
[Á¶È¸]
È¿´ÉÈ¿°ú
[ÀûÀÀÁõ º° °Ë»ö]
¡Û À¯È¿±ÕÁ¾
´Ï½ºÅ¸Æ¾¿¡ °¨¼ö¼ºÀΠĵð´Ù
¡Û ÀûÀÀÁõ
¼ÒȰüĵð´ÙÁõ, ±¸°Äµð´ÙÁõ
¿ë¹ý¿ë·®
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
¡Û ¼ºÀÎ ¹× ¼Ò¾Æ(24°³¿ù ÀÌ»ó) : ´Ï½ºÅ¸Æ¾À¸·Î¼ 1ȸ 40 ¡ 60¸¸ ´ÜÀ§(4 ¡ 6 mL)¸¦ 1ÀÏ 3 ¡ 4ȸ °æ±¸ Åõ¿©ÇÑ´Ù.
¡Û ¿µ¾Æ(28ÀÏ ÀÌ»ó ¡ 24°³¿ù ¹Ì¸¸)
- ±¸° ĵð´ÙÁõ : 1ȸ 10 ¡ 20¸¸ ´ÜÀ§(1 ¡ 2 mL)¸¦ ÇÏ·ç¿¡ 1 ¡ 4ȸ ÀÔ¿¡ ¶³¾îÆ®¸°´Ù.
- ¼ÒȰü ĵð´ÙÁõ : 1ȸ 10¸¸ ´ÜÀ§(1 mL)¸¦ ÇÏ·ç¿¡ 1 ¡ 4ȸ ÀÔ¿¡ ¶³¾îÆ®¸°´Ù.
¡Û »ï۱â Àü¿¡ °¡´ÉÇÑ ÇÑ ¿À·¡ ÀԾȿ¡ ¸Ó¹°°Ô ÇÑ´Ù.
¡Û ¼ÒȰü ĵð´ÙÁõÀÇ °æ¿ì ½Ä°£¿¡ º¹¿ëÇÑ´Ù.
¡Û Áõ»ó¿¡ Àç¹ß¹æÁö¸¦ À§ÇÏ¿© Áõ»óÀÌ »ç¶óÁø ÈÄ¿¡µµ 48½Ã°£ ´õ Ä¡·á¸¦ °è¼ÓÇÑ´Ù.
±Ý±â
ÀÌ ¾à ¶Ç´Â ÀÌ ¾àÀÇ ±¸¼º¼ººÐ¿¡ °ú¹Î¹ÝÀÀ ȯÀÚ
ÀÌ»ó¹ÝÀÀ
1) ¼Òȱâ°è : ¶§¶§·Î ±¸¿ª, ±¸Åä, ½Ä¿åºÎÁø ¼³»ç µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
2) ÇǺΠ: ¸Å¿ì µå¹°°Ô ÇǺÎÁ¡¸·¾ÈÁõÈıº(½ºÆ¼ºì½º-Á¸½¼ ÁõÈıº)ÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÀÌ·¯ÇÑ Áõ»óÀÌ ³ªÅ¸³ °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇϰí ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù.
3) °ú¹Î¹ÝÀÀ : ¹ßÁø, °¡·Á¿ò µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÀÌ·¯ÇÑ Áõ»óÀÌ ³ªÅ¸³¯ °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇÑ´Ù.
4) ±âŸ : µå¹°°Ô ºü¸¥¸Æ(ºó¸Æ), ±â°üÁö¿¬Ãà, Ç÷°üºÎÁ¾(¾È¸é Á¾Ã¢ Æ÷ÇÔ), µÎµå·¯±â, ±ÙÀ°ÅëÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
ÀϹÝÀû ÁÖÀÇ
1) ÀÌ ¾àÀÇ »ç¿ë¿¡ ÀÖ¾î¼ ³»¼º±ÕÀÇ ¹ßÇö µîÀ» ¹æÁöÇϱâ À§ÇÏ¿© °¨¼ö¼ºÀ» È®ÀÎÇϰí Ä¡·á »ó ÇÊ¿äÇÑ ÃÖ¼Ò ±â°£¸¸ Åõ¿©ÇÏ´Â °ÍÀÌ ¹Ù¶÷Á÷ÇÏ´Ù.
2) ´Ï½ºÅ¸Æ¾Àº Àü½ÅÀû(systemic) ĵð´ÙÁõ¿¡´Â È¿°úÀûÀÌÁö ¾Ê´Ù.
ÀӺο¡ ´ëÇÑ Åõ¿©
[ÀӺαݱ⠼ººÐ Á¶È¸]
ÀӽŠÁßÀÇ Åõ¿©¿¡ ´ëÇÑ ¾ÈÀü¼ºÀÌ È®¸³µÇ¾î ÀÖÁö ¾ÊÀ¸¹Ç·Î ÀӺΠ¶Ç´Â ÀÓ½ÅÇϰí ÀÖÀ» °¡´É¼ºÀÌ ÀÖ´Â ¿©¼º¿¡´Â Ä¡·á »óÀÇ À¯ÀͼºÀÌ À§Ç輺À» »óȸÇÑ´Ù°í ÆÇ´ÜµÇ´Â °æ¿ì¿¡¸¸ Åõ¿©ÇÑ´Ù.
¼öÀ¯ºÎ¿¡ ´ëÇÑ Åõ¿©
ÀÌ ¾àÀÇ À§Àå°ü Èí¼öÀ²ÀÌ ³·Áö¸¸, ¸ðÀ¯¸¦ ÅëÇÑ ¿µÇâÀÌ È®ÀεÇÁö ¾Ê¾ÒÀ¸¹Ç·Î ¼öÀ¯ºÎÀÇ °æ¿ì¿¡µµ ½ÅÁßÇÏ°Ô »ç¿ëÇÑ´Ù.
°í·ÉÀÚ¿¡ ´ëÇÑ Åõ¿©
ÀϹÝÀûÀ¸·Î °í·ÉÀÚ´Â »ý¸®±â´ÉÀÌ ÀúÇϵǹǷΠ°¨·®ÇÏ´Â µî ÁÖÀÇÇÑ´Ù.
Àû¿ë»óÀÇ ÁÖÀÇ
»ç¿ë Àü ÃæºÐÈ÷ Èçµé¾î ±ÕÀÏÇÑ Çöʾ×À¸·Î Çϰí, °æ±¸·Î¸¸ »ç¿ëÇÑ´Ù.
º¸°ü ¹× Ãë±Þ»óÀÇ ÁÖÀÇ
Â÷±¤ÇÑ ±â¹Ð¿ë±â, 25¡ÉÀÌÇÏ ½Ç¿Âº¸°ü
±âŸ
µ¿¹°½ÇÇè¿¡¼ ¹ß¾Ï¼ºÀÌ ÀÖ´Â °ÍÀ¸·Î ³ªÅ¸³ »èÄ«¸°À» ÇÔÀ¯Çϰí ÀÖ¾î °Ç°¿¡ ÇØ·Î¿ï ¼ö ÀÖ´Ù.
Related FDA Approved Drug
Á¤º¸¿ä¾à
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
ÄÚµå ¹× ºÐ·ùÁ¤º¸
Á¦Ç°Á¤º¸
º¹¾àÁ¤º¸
Ç׸ñ
³»¿ë
LACTmed ¹Ù·Î°¡±â
[¹Ù·Î°¡±â]
¾à¸®ÀÛ¿ë
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
Ãà¾àº¹¾àÁöµµ
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
º¹¾àÁöµµ
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
ÀӺο¡´ëÇÑÅõ¿©
*
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
 
FDA : Cµî±Þ
(nystatin oral )
*
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
*
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
Pharmacokinetics
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
º¸°ü»ó ÁÖÀÇ
Á¶Á¦½Ã ÁÖÀÇ
½É»çÁ¤º¸
ÇмúÁ¤º¸
Ç׸ñ
³»¿ë
DUR (ÀǾàǰ»ç¿ëÆò°¡)
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
Mechanism of Action
Nystatin¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Nystatin interacts with 14-¥á demethylase, a cytochrome P-450 enzyme necessary for the conversion of lanosterol to ergosterol. This results in inhibition of ergosterol synthesis and increased fungal cellular permeability.
Pharmacology
Nystatin¿¡ ´ëÇÑ Pharmacology Á¤º¸ Nystatin is an antibiotic which is both fungistatic and fungicidal in vitro against a wide variety of yeasts and yeast-like fungi, including Candida albicans , C. parapsilosis , C. tropicalis , C. guilliermondi , C. pseudotropicalis , C. krusei , Torulopsis glabrata , Tricophyton rubrum , T. mentagrophytes . Nystatin acts by binding to sterols in the cell membrane of susceptible species resulting in a change in membrane permeability and the subsequent leakage of intracellular components. On repeated subculturing with increasing levels of nystatin, Candida albicans does not develop resistance to nystatin. Generally, resistance to nystatin does not develop during therapy. However, other species of Candida (C. tropicalis , C. guilliermondi , C. krusei , and C. stellatoides ) become quite resistant on treatment with nystatin and simultaneously become cross resistant to amphotericin as well. This resistance is lost when the antibiotic is removed. Nystatin exhibits no appreciable activity against bacteria, protozoa, or viruses.
Metabolism
Nystatin¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Cytochrome P450 3A4 (CYP3A4)
Half-life
Nystatin¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ Not Available
Absorption
Nystatin¿¡ ´ëÇÑ Absorption Á¤º¸ Nystatin is not absorbed from intact skin or mucous membrane
Pharmacokinetics
NystatinÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
ÀÛ¿ë¹ßÇö½Ã°£ : ĵð´ÙÁõÀÇ Áõ»ó ¿ÏÈ : 24-72 ½Ã°£
Èí¼ö :
Á¡¸·À̳ª Á¤»ó ÇǺθ¦ ÅëÇØ¼´Â Èí¼öµÇÁö ¾Ê´Â´Ù.
À§Àå°ü¿¡¼ °ÅÀÇ Èí¼öµÇÁö ¾Ê´Â´Ù.
¼Ò½Ç : ¹Ìº¯Èü·Î º¯¹è¼³
Toxicity
Nystatin¿¡ ´ëÇÑ Toxicity Á¤º¸ Not Available
Drug Interactions
Nystatin¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
CYP450 Drug Interaction
[CYP450 TableÁ÷Á¢Á¶È¸]
Food Interaction
Nystatin¿¡ ´ëÇÑ Food Interaction Á¤º¸ Take without regard to meals.
Drug Target
[Drug Target]
Description
Nystatin¿¡ ´ëÇÑ Description Á¤º¸ Nystatin is a polyene antifungal drug to which many molds and yeasts are sensitive, including Candida spp. Nystatin has some toxicity associated with it when given intravenously, but it is not absorbed across intact skin or mucous membranes. It is considered a relatively safe drug for treating oral or gastrointestinal fungal infections.
Drug Category
Nystatin¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anti-Bacterial AgentsAntifungal AgentsIonophores
Smiles String Canonical
Nystatin¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CC1OC(=O)CC(O)CC(O)CC(O)CCC(O)C(O)CC(=O)CC(O)C(C(O)CC(OC2OC(C)C(O)C(N)C2O)C=CC=CC=CC=CCCC=CC=CC(C)C(O)C1C)C(O)=O
Smiles String Isomeric
Nystatin¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ C[C@H]1OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@H](O)[C@@H](O)CC(=O)C[C@@H](O)[C@@H]([C@@H](O)C[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](N)[C@@H]2O)\C=C\C=C\C=C\C=C\CC\C=C\C=C\[C@H](C)[C@H](O)[C@H]1C)C(O)=O
InChI Identifier
Nystatin¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C47H75NO17/c1-27-17-15-13-11-9-7-5-6-8-10-12-14-16-18-35(65-47-45(60)42(48)44(59)30(4)64-47)26-39(56)41(46(61)62)38(55)24-34(52)23-37(54)36(53)20-19-31(49)21-32(50)22-33(51)25-40(57)63-29(3)28(2)43(27)58/h5-6,8,10-18,27-33,35-39,41-45,47,49-51,53-56,58-60H,7,9,19-26,48H2,1-4H3,(H,61,62)/b6-5+,10-8+,13-11+,14-12+,17-15+,18-16+/t27?,28?,29?,30-,31?,32?,33?,35?,36?,37?,38?,39?,41?,42+,43?,44-,45+,47?/m1/s1/f/h61H
Chemical IUPAC Name
Nystatin¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ (21E,23E,25E,27E,31E,33E)-20-[(3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-4,6,8,11,12,16,18,36-octahydroxy-35,37,38-trimethyl-2,14-dioxo-1-oxacyclooctatriaconta-21,23,25,27,31,33-hexaene-17-carboxylic acid
»ç¿ëÀÚÄÁÅÙÃ÷
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2025-10-13
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
¾Ë¸²
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù.
°æ°í
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡± ¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â ·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ